Rejuvenate Bio

Rejuvenate Bio is pursuing one of biotechnology’s most ambitious goals: treating the root causes of aging itself.

Founded by a team of scientists and entrepreneurs from Harvard, MIT, and Caltech, and co-founded by renowned geneticist George Church, Rejuvenate is developing gene therapies designed to combat multiple age-related diseases with a single treatment.

The company has already raised more than $40 million from venture-capital firms including VCapital, Digitalis Ventures, Kendall Capital Partners, and KdT Ventures. Now it’s seeking additional capital from individual investors like you.

At its core, Rejuvenate is built around the idea that many chronic diseases share common biological causes. Rather than creating separate drugs for heart disease, kidney disease, metabolic disorders, and other conditions, the company is developing gene therapies that target the aging process itself.

Its treatments use carefully selected genes delivered through viral vectors to help restore healthier cellular function. In simple terms, the goal is to reprogram the body to function more like it did when it was younger.

The company’s strategy is somewhat unique. That’s because it’s pursuing both animal-health and human-health opportunities. Rejuvenate initially focused on companion animals, particularly dogs suffering from age-related conditions such as heart disease and metabolic disorders.

Management believes this creates a faster path to commercialization while simultaneously generating valuable data that can support future human therapies. In fact, the company often describes its approach as a way to “double-dip” on research, with canine studies helping advance both veterinary and human programs.

The market opportunity is substantial. The global gene therapy market is already worth more than $10 billion annually and is expected to grow rapidly as more therapies reach commercialization.

Meanwhile, the broader longevity and healthy-aging market is measured in the hundreds of billions of dollars, fueled by aging populations and rising healthcare costs. The pet-health market is also sizable, valued at roughly $300 billion. Owners are increasingly willing to spend significant amounts to extend the lives and health of their animals. By targeting both human and veterinary applications, Rejuvenate has multiple pathways to create value.

To make money, Rejuvenate’s business model combines product sales, development partnerships, milestone payments, and royalties. The company has secured more than $130 million in contracted development and commercial milestone payments, and management projects royalty revenue beginning later this decade. This approach could enable the company to generate revenue well before its broader vision of human anti-aging therapies reaches the market.

Rejuvenate’s platform has produced disease-reversal results in dogs and life-extension results in mice, providing early evidence that its approach may work across multiple species.

The company has received more than $13 million in non-dilutive funding from the U.S. Department of Defense and U.S. Special Operations Command to explore applications related to endurance, recovery, and resilience in both humans and working dogs. It’s also received more than $5 million in cumulative payments and in-kind services from partners.

Team Background

Noah Davidsohn - Co-Founder & Chief Scientific Officer

Before co-founding Rejuvenate, Noah served as a Staff Scientist at the Wyss Institute for Biologically Inspired Engineering. Prior to that, he was a Postdoctoral Fellow in the laboratory of George Church at Harvard Medical School, where he focused on genetic therapies for age-related diseases and genome-engineering technologies including CRISPR. Earlier in his career, he conducted doctoral research in synthetic biology and mammalian DNA circuits.

Noah earned a Ph.D. in Synthetic Biology from Massachusetts Institute of Technology after beginning his doctoral studies at Princeton University. He received a bachelor’s degree in Applied Physics from California Institute of Technology.

Daniel Oliver - Co-Founder & CEO

Prior to founding Rejuvenate, Daniel was an Entrepreneur-in-Residence at the Wyss Institute for Biologically Inspired Engineering.

Before that, he was a fellow at Harvard Business School, where he focused on commercializing emerging technologies. He also co-founded Voxel8, a company making 3D-printed functional electronics, and earlier worked as an aerospace engineer.

Daniel earned an MBA from Harvard Business School. He also holds an undergraduate degree from California Institute of Technology.

George Church - Co-Founder & Scientific Advisor

One of the world’s leading geneticists and synthetic biologists, George has founded dozens of biotechnology companies and is widely regarded as a pioneer in genomics, gene therapy, and synthetic biology.

In addition to his work with Rejuvenate, George serves as the Robert Winthrop Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Massachusetts Institute of Technology.

He is also a founding core faculty member of the Wyss Institute for Biologically Inspired Engineering. Over the course of his career, he has launched roughly 50 biotechnology companies and helped pioneer many of the technologies underlying modern DNA sequencing and synthetic biology.

George earned a Ph.D. in Genetics from Harvard University and a bachelor’s degree from Duke University.

Co-Investors

VCapital

A VC firm that's invested $45 million into more than a dozen early-stage companies.

Digitalis Ventures

A health-focused VC firm with roughly $300 million in capital committed across multiple funds and more than 50 companies in its portfolio.

Kendall Capital Partners

A Boston-based VC backing early-stage biotech companies.

KdT Ventures

A venture-capital firm investing in seed-stage startups. More than 100 companies in its portfolio.